Expression of CD30 as a biomarker to predict response to brentuximab vedotin

Histopathology. 2016 Jul;69(1):155-8. doi: 10.1111/his.12914. Epub 2016 Jan 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism*
  • Brentuximab Vedotin
  • Disease Progression
  • Female
  • Hodgkin Disease / diagnosis
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / immunology
  • Humans
  • Immunoconjugates / administration & dosage*
  • Ki-1 Antigen / metabolism*
  • Logistic Models
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / immunology
  • Male
  • Middle Aged
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Immunoconjugates
  • Ki-1 Antigen
  • Brentuximab Vedotin